Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Jak/Stat Pathway

Chemical Structure Cat. No. Product Name CAS No.
STAT3-IN-1 Chemical Structure
BCP42674 STAT3-IN-1 2059952-75-7
STAT3-IN-1 is a novel selective and orally active STAT3 inhibitor.
BD750 Chemical Structure
BCP42671 BD750 892686-59-8
BD750 is an immunosuppressant and a dual inhibitor of JAK3 and STAT5 that inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation with IC50 of 1.5 μM and 1.1 μM for mouse and human T-cell proliferation, respectively.
Parsaclisib hydrochloride Chemical Structure
BCP42656 Parsaclisib hydrochloride 1995889-48-9
Parsaclisib, also known as INCB050465, is a novel PI3Kδ inhibitor which synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL.
SB1317 Chemical Structure
BCP42651 SB1317 1204918-72-8
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.
SHR0302 Chemical Structure
BCP34833 SHR0302 1445987-21-2
SHR0302 is a novel potent JAK inhibitor, blocking JAK/STAT3 signaling, suppressing proliferation, migration and collagen production, and inducing the apoptosis of hepatic stellate cells.
SI-109 Chemical Structure
BCP40461 SI-109 2429877-30-3
SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM).
AST5902 Chemical Structure
BCP39664 AST5902 AST5902
Alflutinib is mainly metabolized via CYP3A4 to form its active metabolite AST5902.
JND3229 Chemical Structure
BCP38649 JND3229 2260886-64-2
JND3229 is a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy (IC50 = 5.8 nM).
Almonertinib Chemical Structure
BCP38312 Almonertinib 1899921-05-1
Almonertinib is an EGFR tyrosine kinase inhibitor. Upon administration, HS-10296 binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells.
Epertinib hydrochloride Chemical Structure
BCP37982 Epertinib hydrochloride 2071195-74-7
Epertinib hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4. It shows potent antitumor activity.
123下一页末页共 257 条记录 1 / 26 页 
0086-15971444841